Shh, Watch Quietly, Expecting Renzilumab After Remdesivir! Check the Stocks!

- The COVID-19 treatment developed by the US biotech company Humanigen has been recognized for its safety in the interim results of its Phase 3 clinical trial.

- Domestic joint investment of 4.9 billion KRW by KPM Tech and Telcon RF Pharmaceutical

- Stock prices soar amid expectations for the COVID-19 treatment...

▶▶ September “Limit Up” Nasdaq Listing Approval in the US, COVID-19 Treatment to Shine After Remdesivir! ▶Free Trial Application◀

Those who applied < KPM Tech (042040) > hit the limit up in just 3 days! Achieved 78% profit!

Congratulations to everyone who applied for the free trial. ^^

※ For those who missed the “COVID-19 treatment,” it’s okay. We are going out strong once again.

※ It finally starts. KPM Tech (042040) follow-up stock hits limit up on Wednesday. ※

▶▶ Starting with a huge ‘Limit Up’ on September 23, a vaccine development company supported from abroad! ‘ㅇㅇㅇㅇㅇㅇ’ related stock! ▶ Free Trial Application◀

According to US Business Wire, the US Data and Safety Monitoring Board (DSMB) unanimously expressed satisfaction with the interim results of Humanigen’s COVID-19 treatment candidate ‘Lenzilumab’ in its Phase 3 clinical trial.

Lenzilumab, developed by Humanigen, is expected to suppress and prevent the ‘cytokine storm,’ an excessive immune response occurring in COVID-19 patients. It is currently undergoing Phase 3 clinical trials after receiving approval from the US Food and Drug Administration (FDA).

※ It finally starts. ‘Why did KPM Tech rise? It explodes on Wednesday! Lenzilumab COVID-19 treatment!

※ [Click] [COVID-19 Phase 3 clinical trial efficacy and safety proven, Nasdaq listing approval!] Apply immediately!

“It was very difficult to trade stocks alone.” So I thought to get advice from an expert and first applied for a 3-day free trial! Wow! Experts are really different. I am still receiving the service and I think it was a great decision. Thank you very much.

(VIP civil servant Park Han-young, 43 years old, member)

Now think this is the last chance. If you miss this opportunity, you have to give up.

Exactly on “September 23,” it will explode! Don’t miss it and regret it, just buy even with 100,000 KRW!

▶▶ “September 23 Limit Up” Offered only until today and then closed. [Receive stocks related to ‘Phase 3 clinical trial issue highlighted! Safety verified for triple limit up!’] ▶ Receive stocks◀

[AI recent limit up hits]

*20.09.16 Daesung Fintech (104040) Limit Up hit!

*20.09.15 Jeju Semiconductor (080220) Limit Up hit!

*20.09.14 Hyundai Industry (170030) Limit Up hit!

*20.09.11 Borak (002760) Limit Up hit!

*20.09.10 Dong-A Chemical (041930) Limit Up hit!

*20.09.09 SDN (099220) Limit Up hit!

*20.09.08 Chorokbaem (047820) Limit Up hit!